Danaher To Acquire Medical Tech Firm Masimo For Nearly $10 Billion

Got story updates? Submit your updates here. ›

Danaher, a $150 billion conglomerate, announced it will acquire Masimo, a global medical technology company specializing in patient-monitoring devices, for nearly $10 billion. The deal will see Danaher pay $180 per share in cash, a 40% premium over Masimo's previous closing price.

Why it matters

The acquisition of Masimo will expand Danaher's reach in the growing medical technology market, adding patient-monitoring devices and related software to its portfolio of biotechnology, life sciences and diagnostics products. The deal also comes amid a broader wave of consolidation in the healthcare industry, as larger firms seek to expand their capabilities and market share.

The details

Under the terms of the deal, Danaher will pay $180 per share in cash for Irvine, California-based Masimo, a nearly 40% premium to the company's previous closing price. Masimo specializes in patient-monitoring devices such as pulse oximeters, noninvasive sensors and related software. The acquisition will allow Danaher to further diversify its product offerings and capitalize on the growing demand for advanced medical technologies.

• Danaher announced the $10 billion deal to acquire Masimo on February 17, 2026.
• The transaction is expected to close in the second half of 2026, subject to regulatory approvals and other customary closing conditions.

What’s next

The acquisition is expected to close in the second half of 2026, pending regulatory approvals and other customary closing conditions.